Navigation Links
Micromet, Inc. Reports Third Quarter 2008 Financial Results
Date:11/6/2008

l stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT 293, to TRACON Pharmaceuticals, Inc. MT 293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT 203 being developed in collaboration with Nycomed. MT 203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This press release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the development of our BiTE antibody technology, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, and our plans regarding future presentations of clinical data. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," "suggests," "could," or "consider" or the negative of those words or other similar words t
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
2. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
3. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
4. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
5. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
8. EntreMed Reports Third Quarter 2008 Financial Results
9. CV Therapeutics Reports 2008 Third Quarter Financial Results
10. Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase
11. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Opertech Bio, Inc., a company that ... approach to sensory evaluation, today announced the issuance ... Patent and Trademark Office, encompassing high-throughput sensory discrimination ... taste evaluation technology called Microtiter Operant Gustometer or ... for rapid characterization of taste sensory properties,” said ...
(Date:9/2/2014)... - Oncothyreon Inc. (Nasdaq: ONTY ) announced today that ... will present at the Rodman & Renshaw 16 th ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... presentation will be accessible by visiting the Oncothyreon website ... About Oncothyreon Oncothyreon is a biotechnology ...
(Date:9/2/2014)... Mount, NC (PRWEB) September 02, 2014 ... establishment of its 11th clinical research site: PMG Research ... assumed ownership and operation of the clinical research department ... further expanding PMG’s presence in eastern North Carolina. This ... patients. For the patients in Rocky Mount and the ...
(Date:9/2/2014)... The inventors of tinAway, a novel ... are seeking support for development costs through a crowdfunding ... http://igg.me/at/tinaway ), was launched on September 1, 2014. , ... and is based on ten years of neuroscience ... and software engineers, Dr. Ian Dixon and Mr. Tony ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... QUEBEC CITY, Aug. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... on,endocrinology and oncology, today reported financial and operating results,for the ... Highlights, - Advancement of cetrorelix Phase 3 program ... trial: patient enrollment completed; - ...
... ST. LOUIS, Aug. 12 At the Board ... quarterly cash dividend of,$.13 per share. The dividend ... record on September 2, 2008., About Sigma-Aldrich: ... company. Our biochemical and organic chemical products and ...
... LI-COR Biosciences continues to,expand its offering of ... new IRDye(R) 680 Donkey Anti-Chicken IgG, IRDye ... IgG, and IRDye 800CW Goat,Anti-Rat IgG antibodies ... detection for multiple applications including,quantitative Westerns, In-Cell ...
Cached Biology Technology:AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 2AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 3AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 4AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 5AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 6AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 7
(Date:8/29/2014)... understand how the repeated climatic shifts over the ... of genetic diversity, a team of researchers led ... Ana Carnaval developed a new biodiversity metric called ... which the genetic variation within species is restricted ... professor of biology, and 14 other researchers from ...
(Date:8/29/2014)... news release is available in German . ... key players in the natural nitrogen cycle on Earth ... specialist bacteria were thought to depend on nitrite as ... led by Holger Daims, a microbiologist at the University ... use hydrogen as an alternative source of energy. The ...
(Date:8/29/2014)... such as the prolific bloomer Emiliania huxleyi , ... discovered. The finding contradicts the common view that ... on scarce supplies of thiamine in the ocean to ... about the ocean," says CIFAR Senior Fellow Alexandra ... paper with CIFAR fellows John Archibald (Dalhousie ...
Breaking Biology News(10 mins):CCNY team defines new biodiversity metric 2Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3
... fittest survive has been called into question by new research ... A collaboration between the Universities of Exeter and Bath in ... in the US, challenges our current understanding of evolution by ... The work represents a new approach to studying evolution that ...
... done by Mark Lusk and colleagues at the Colorado ... solar cells. Their latest work describes how the size ... energy to electrons to generate electricity. The results ... ACS Nano . The advance provides evidence ...
... NeoProteomics Inc., a biomarker development and software ... Case Western Reserve University. The deal has potential ... diabetes, and inflammatory diseases. Proteomics is the ... structures of biological systems. NeoProteomics, founded in 2006 ...
Cached Biology News:Research shows not only the fittest survive 2Size matters: Smaller particles could make solar panels more efficient 2Case Western Reserve and NeoProteomics announce exclusive option 2
...
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
...
Request Info...
Biology Products: